当前位置: X-MOL 学术OncoTargets Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation
OncoTargets and Therapy ( IF 4 ) Pub Date : 2021-09-15 , DOI: 10.2147/ott.s328839
Weitao Zhuang 1, 2 , Chao Zhang 3 , Yong Tang 1 , Dan Tian 1 , Zihua Lan 1, 2 , Cheng Zeng 1 , Guibin Qiao 1
Affiliation  

Abstract: Development of targeted therapies for squamous cell lung cancer (SqCLC) is currently limited by the prevalence of activating mutations and their predicting power of treatment efficacy. In the present study, we describe a case of treatment-naïve stage IIIB SqCLC that harbored a rare epidermal growth factor receptor (EGFR) p.E746_S752delinsV mutation with clinical complete response to neoadjuvant gefitinib. Pathological complete response was confirmed after surgical resection. No disease recurrence was documented after 20-month follow-up. This report suggested that first-generation EGFR tyrosine kinase inhibitor (TKI) could be an option in neoadjuvant context for advanced SqCLC patients harboring EGFR p.E746_S752delinsV mutation and highlighted the clinical benefits of EGFR testing in SqCLC patients who are females and never/former light smokers.

Keywords: epidermal growth factor receptor, squamous cell lung cancer, tyrosine kinase inhibitor, next generation sequencing, EGFR p.E746_S752delinsV mutation, EGFR, SqCLC, TKI, NGS


中文翻译:

携带 EGFR p.E746_S752delinsV 突变的 SqCLC 患者对吉非替尼的临床和病理学完全缓解

摘要:鳞状细胞肺癌 (SqCLC) 靶向疗法的开发目前受到激活突变的普遍性及其对治疗效果的预测能力的限制。在本研究中,我们描述了一个未经治疗的 IIIB 期 SqCLC 病例,该病例含有罕见的表皮生长因子受体 (EGFR) p.E746_S752delinsV 突变,对新辅助治疗吉非替尼具有临床完全反应。手术切除后证实病理完全缓解。在 20 个月的随访后没有记录到疾病复发。该报告表明,第一代 EGFR 酪氨酸激酶抑制剂 (TKI) 可能是携带 EGFR p.E746_S752delinsV 突变的晚期 SqCLC 患者新辅助治疗的一种选择,并强调了 EGFR 检测对女性且从未/以前光的 SqCLC 患者的临床益处吸烟者。

关键词:表皮生长因子受体,鳞状细胞肺癌,酪氨酸激酶抑制剂,二代测序,EGFR p.E746_S752delinsV突变,EGFR,SqCLC,TKI,NGS
更新日期:2021-09-14
down
wechat
bug